Study of Patritumab Deruxtecan Plus Pembrolizumab with Other Anticancer Agents in Participants with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Trial Identifier: 1022-010
Sponsor: MSD
Collaborator:
Daiichi Sankyo
Start Date: March 2025
Primary Completion Date: December 2029
Study Completion Date: December 2034
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03080
Korea, Republic of, Seoul Seoul, Korea, Republic of, 05505
Korea, Republic of, Seoul Seoul, Korea, Republic of, 03722
Spain, Cataluna Badalona, Cataluna, Spain, 08916
Spain, Cordoba Cordoba, Spain, 14004
Spain, Madrid, Comunidad de Madrid, Madrid, Comunidad de, Spain, 28027
Taiwan, Taichung Taichung, Taiwan, 407
Taiwan, Tainan Tainan, Taiwan, 704
Taiwan, Taipei Taipei, Taiwan, 112
United States, CA Santa Monica, CA, United States, 90404
United States, IL Skokie, IL, United States, 60077
United States, MT Billings, MT, United States, 59102
United States, OR Tigard, OR, United States, 97223
United States, TN Nashville, TN, United States, 37203
United States, TX Dallas, TX, United States, 75246
United States, TX Houston, TX, United States, 77030
United States, VA Norfolk, VA, United States, 23502